Printer Friendly

SMITHKLINE BEECHAM DRUG TESTING INDEX SHOWS HIGH POSITIVE POST-ACCIDENT DRUG TESTS

 SMITHKLINE BEECHAM DRUG TESTING INDEX SHOWS HIGH POSITIVE
 POST-ACCIDENT DRUG TESTS
 PHILADELPHIA, Sept. 14 /PRNewswire/ -- Workers in safety- sensitive transportation jobs who are tested for drugs after being involved in an accident are nearly twice as likely to test positive as similar workers who are randomly tested under federal guidelines, SmithKline Beecham Clinical Laboratories said today, in releasing its Drug Testing Index.
 The SmithKline Beecham Drug Testing Index also showed that unannounced random testing detected significantly more positive results than did scheduled periodic testing.
 According to the Drug Testing Index, one of every six transportation workers (16.58 percent) tested because of a reasonable suspicion of drug use, in fact, tested positive.
 Statistics on testing categories are available only for the safety-sensitive transportation industry, whose overall 1992 rate of positive drug results (2.5 percent) is significantly lower than the general work force (10.8 percent), SmithKline Beecham Clinical Laboratories said.
 Of the general U.S. work force SB tested, including transportation workers, there was a modest decrease -- from 9.3 percent for the first six months of 1991 to 8.9 percent for the first six months of 1992 -- but a substantial decline from 1987, when the overall drug-positive rate was 18.1 percent, according to the SmithKline Beecham Drug Testing Index.
 "Our objective findings indicate there are still drugs at work, but clear signs of progress," said W. Vickery Stoughton, new president of SmithKline Beecham Clinical Laboratories. "Where comprehensive programs have been in place -- as in the transportation industry -- the numbers are far lower," he added.
 "It is not surprising that spot checking or testing after suspicious behavior reveals higher numbers than announced testing. But the higher prevalence following accidents suggests there is a relationship between performance and drug use," Stoughton said.
 Although laboratory results can be reversed by medical review, the vast majority, particularly the most common drugs, marijuana and cocaine, tend to remain positive throughout the process.
 Other findings from testing reflected in the SmithKline Beecham Drug Testing Index -- January-June 1992:
 PREVALENCE RATES
 Safety-sensitive transportation
 workers 2.5 percent
 General work force 10.8 percent
 Combined U.S. workers 8.9 percent
 POSITIVE DRUG TEST RESULTS BY TESTING CATEGORY
 Safety-sensitive transportation jobs
 (More than 250,000 tests)
 Pre-employment 2.99 percent
 Periodic (those pre-warned) 1.80 percent
 Random 2.49 percent
 Post-accident 4.37 percent
 For cause 16.58 percent
 Returned to duty 2.81 percent
 POSITIVE RESULTS BY DRUG CATEGORY
 (For safety-sensitive transportation workers)
 marijuana 51.9 percent
 cocaine 29.7 percent
 opiates 12.1 percent
 amphetamines 3.8 percent
 PCP 2.5 percent
 General Work Force
 (Including safety-sensitive transportation workers)
 (More than 1.2 million tests)
 marijuana 40.0 percent
 cocaine 26.5 percent
 benzodiazepines, a class of
 drugs which includes
 tranquilizers such as Valium
 and Librium 12.7 percent
 opiates 9.2 percent
 barbiturates 4.9 percent
 propoxyphene (e.g. Darvon) 2.3 percent
 methadone 2.0 percent
 amphetamines 1.7 percent
 PCP 0.6 percent
 methaqualone less than one tenth of 1 percent
 POSITIVE RESULTS BY GEOGRAPHIC REGION
 Southeast 9.9 percent
 Central 9.2 percent
 Northeast 8.1 percent
 West 6.5 percent
 DRUG TRENDS
 Over the last 5-1/2 years, SmithKline Beecham Clinical Laboratories has tested more than 7 million samples from American workers. Over that period, and based on those samples, the overall drug-positive rate has declined significantly:
 1987 18.1 percent
 1988 13.6 percent
 1989 12.7 percent
 1990 11.0 percent
 1991 8.8 percent
 1992 (January-June) 8.9 percent
 SmithKline Beecham Clinical Laboratories releases its Drug Testing Index every six months as a service to government, industry and the media. The 1992 Index tracked results of more than 1.2 million tests conducted by SmithKline Beecham Clinical Laboratories in the first six months of the year.
 SmithKline Beecham Clinical Laboratories, with drug testing facilities in 18 of is 24 laboratories, has performed more drug testing than any other company in the United States. The company's six federally (NIDA) certified laboratories, are located in Philadelphia, Atlanta, Chicago, Dallas, Los Angeles and St. Louis.
 SmithKline Beecham Clinical Laboratories is part of SmithKline Beecham, one of the world's leading health care companies. SmithKline Beecham discovers, develops, manufactures and markets human and animal pharmaceuticals and over-the-counter medicines as well as clinical laboratory testing services.
 /delval/
 -0- 9/14/92
 /CONTACT: Tobey Dichter of SmithKline Beecham Clinical Laboratories, 215-962-7511 or 800-877-7478 or, after hours, 215-922-1633; or Ellen Lathem for SmithKline Beecham Clinical Laboratories, 202-944-5101/ CO: SmithKline Beecham Clinical Laboratories ST: Pennsylvania IN: MTC SU:


TW -- DC011 -- 9039 09/14/92 10:28 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 14, 1992
Words:763
Previous Article:FPL HURRICANE SUMMARY
Next Article:U.S. HEALTHCARE ANNOUNCES NEW JERSEY APPROVAL OF RATE INCREASE
Topics:


Related Articles
WINN-DIXIE EXPANDS DRUG TESTING PROGRAM; NOW MOST EXTENSIVE AMONG AMERICA'S RETAILERS
SMITHKLINE BEECHAM DRUG TESTING INDEX SHOWS TREND FLAT FOR U.S. WORK FORCE
SMITHKLINE BEECHAM DRUG TESTING INDEX TREND AND RATE CHARTS -- JANUARY - JUNE 1993
SMITHKLINE BEECHAM ANNOUNCES DECLINE IN WORKPLACE POSITIVE DRUG TESTS
ACOG SIGNS DOPING CONTROL AGREEMENT WITH MOREHOUSE SCHOOL OF MEDICINE AND SMITHKLINE BEECHAM CLINICAL LABORATORIES
SMITHKLINE BEECHAM ANNOUNCES CONTINUED DECLINE IN WORKPLACE POSITIVE DRUG TESTS
SMITHKLINE BEECHAM ANNOUNCES DRAMATIC DECLINE IN WORKPLACE POSITIVE DRUG TESTS
SMITHKLINE BEECHAM ANNOUNCES DRAMATIC DECLINE IN WORKPLACE POSITIVE DRUG TESTS
SMITHKLINE BEECHAM CLINICAL LABORATORIES ACCREDITED TO PERFORM OLYMPIC DRUG TESTING
Drug Detection in Workplace Continues Downward Trend, SmithKline Beecham Data Show

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters